An investigative synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum, was associated with greater improvements than placebo in patients with skin-predominant dermatomyositis — some of it statistically significant — in a phase 2 double-blind, randomized, controlled study published in the Journal of Investigative Dermatology.
Patients taking lenabasum experienced greater reductions in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) — a validated outcome designed to assess inflammatory skin involvement in the rare autoimmune disease — and improvements in patient-reported and biomarker outcomes compared with those on placebo, dermatologist Victoria P. Werth, MD, and her coinvestigators reported
